In the current study, we adapted our scrib−/RasV12 model and the larval screening platform we developed to screen for compounds that synergistically inhibit tumour growth together with the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib. The gene discussed is MAP2K7; the disease is neoplasm.